Japan has designated CNS-Active Agents as Shitei Yakubutsu to ensure product quality, efficacy, and safety in pharmaceuticals and medical devices.
Japan Tightens Controls on CNS-Active Substances
New rules classify stimulants and psychoactive compounds as “Shitei Yakubutsu” to ensure safety.
What changed
CNS-Active Agents designated as Shitei Yakubutsu under the 1960 Act.
Strict oversight to ensure quality, efficacy, and safety of products.
Applies to pharmaceuticals and medical devices containing these agents.
Who it affects
Importers of pharmaceuticals and medical devices must ensure compliance with the new designation.
Manufacturers of products containing CNS-Active Agents are subject to stricter oversight.
Key dates
Regulation Analysis: Designation of CNS-Active Agents as Shitei Yakubutsu in Japan
Japan regulates certain central nervous system (CNS)-active agents as Shitei Yakubutsu (designated substances) under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (1960, Law No. 145) to prevent abuse and ensure public safety. The following substances have been proposed for designation, with strict prohibitions on their manufacture, import, sale, possession, and use, except for specified "proper uses"1.
1. Designated Substances (Shitei Yakubutsu)
The Ministry of Health, Labour and Welfare (MHLW) has proposed the following three CNS-active agents for designation as Shitei Yakubutsu1:
| Substance Name | Abbreviation |
|---|---|
| N-Isopropyl-5-methoxytryptamine | 5-MeO-NiPT |
| 1-(2-Diethylamino)ethyl-2-(3,4-methylenedioxyphenyl)methyl-5-nitrobenzimidazole | Methylenedioxynitazene |
| 2-1-5-nitro-1-1benzimidazole | Fluetonitazepyne / N-pyrrolidino-fluetonitazene |
2. Prohibited Activities
Under the Act, the following activities are banned for the designated substances unless conducted under "proper uses"1:
- Manufacture
- Import
- Sale
- Simple ownership (possession without lawful purpose)
- Use
3. Permitted "Proper Uses"
The Act exempts the following activities from the prohibition, provided they meet the specified criteria1:
- Research or Testing by Authorized Entities
- Conducted by:
- Government agencies or local governments
- Technical colleges
- Inter-university research institutes
- Independent administrative agencies
- Local independent administrative agencies
- Tests Under the Act
- Activities directly related to compliance with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.
- Forensic Use
- Use in legal or criminal investigations (e.g., evidence analysis).
- MHLW-Approved Uses
- Any use deemed by the Minister of Health, Labour and Welfare to pose no risk of harm to the human body.
4. Regulatory Authority and Enforcement
- Designating Authority: Minister of Health, Labour and Welfare (MHLW)1.
- Enforcement: Violations of the prohibition may result in penalties under the Act, though specific penalties are not detailed in the provided sources.
Summary Table: Key Requirements
| Regulation | Key Requirement | Deadline/Threshold | Authority |
|---|---|---|---|
| Act on Securing Quality, Efficacy and Safety of Products (Law No. 145) | Prohibits manufacture, import, sale, possession, and use of designated CNS-active agents1. | Immediate upon designation | MHLW |
| Exempts "proper uses" (research, testing, forensic, or MHLW-approved uses)1. | Not specified | MHLW |
Summary Answer
Japan designates certain CNS-active agents as Shitei Yakubutsu under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, prohibiting their manufacture, import, sale, possession, and use except for specific "proper uses" such as government-led research, forensic activities, or MHLW-approved applications1. The three substances proposed for designation are 5-MeO-NiPT, Methylenedioxynitazene, and Fluetonitazepyne1. Compliance is enforced by the MHLW, with violations subject to penalties under the Act.
Sources
- ↩ WTO TBT notification 26-03151 — Japan https://members.wto.org/crnattachments/2026/TBT/JPN/26_03151_00_e.pdf